Our group recently published the results of the VICTOR-1 study, showing that the all-oral metronomic combination of VNR and CAPE is highly active in a population of hormone receptor (HR)-positive/HER2-negative advanced breast cancer patients, with a very low incidence of Grade 3–4 toxicity [4]. The gene discussed is ERBB2; the disease is breast cancer.